skip to navigation skip to content


These ventures have just started at Accelerate Cambridge. They are at various stages of development, with some having already raised their first seed round.

3D FlashLight

3D FlashLight is a venture developing a new three-dimensional (3D) scanning technology, inexpensive, fast and high resolution. From the technical point of view, our new technology is capable of retrieving sub-millimetre 3D geometrical features of surfaces. As highly accurate surface reconstruction can be useful for countless fields as surface inspection, quality control in manufacturing, biometric sensors, volumetric reconstruction, cultural heritage and medical analysis.

The acquisition process of data for retrieving the 3D geometry of the surface under inspection makes our technology overcome current limitation in the market of short-range 3D scanners. In fact, it consists of flashing LED light sources synchronised with a digital camera. This implies both inexpensiveness and high-speed acquisition (fraction of a second). The 3D reconstruction itself is also very fast as it is implemented on parallel computing platform. We built a proof of concept prototype that we are improving considering a second version with improved features.

Competitor 3D scanners are based on structured light and laser technologies and one way to assess their value is through accuracy, speed, cost and customisability ranges. Regarding accuracy, 3D FlashLight can obtain comparable results with laser scanners, but this has to be considered with the fact that to get this accuracy a laser scanner needs few tens of minutes whereas 3D FlashLight has comparable acquisition time with structured light technology. Given the inexpensive components, the hardware cost of 3D FlashLight is also very low compared with the competition. Finally, since 3D FlashLight is made of components highly adjustable, customizability is very high as a 3D scanner based on our technology can be shaped to fit onto existing framework of industrial pipeline or robotic arms.

3D FlashLight logo

Acting Systems™

Acting Systems™ helps social media marketers create original scripts for content by using the demand expressed by audiences on social media. Our solution uses artificial intelligence, machine learning, and content production processes. Each one of our scripts is composed of granular story elements, clearly backed by audience demand.

Visit the Acting Systems website

Acting Systems logo


Antiverse is developing a revolutionary technology to predict antibody drug hits in a single day rather than in months through the traditional methods. A combination of cell-free technology and cutting-edge machine learning is used to develop a proprietary model that recognises and predicts features of antibody-antigen interaction. Ultimately, the customers, who are pharma companies and Contract Research Organisations (CROs), provide us with the sequence of the antigen and Antiverse provides the customers with the sequence of antibodies which bind the antigen with a high affinity. A pharma company and several CROs have already expressed a strong interest in using the service and will also provide support to develop the model as rapidly as possible. Antiverse's technology will greatly speed up antibody hit discovery and thus enable the development of more, and better, antibody therapeutics against cancer, inflammation and rare diseases.  

Antiverse logo

Empire Healthcare and Technology Group

Our business provides medical healthcare services using online platform technologies. We provide tiered services depending on patient choice and budget. Users can access local and international healthcare from family doctors to international experts. Patients will be able to access our online services from remote locations shortening the time and costs involved to be seen by a doctor.

Empire Healthcare and Technology Group


Exantas uses modern software engineering techniques to provide equity investment solutions and investing packages. A combination of fundamental and technical investment strategies are analysed with artificial intelligence (AI) algorithms, enabling a fully automated investment process. Using quant-driven algorithms removes human predisposition to heuristics, allowing for efficient and unbiased portfolio construction. AI algorithmic investing removes investor irrationality, a widely reported phenomenon in behavioural finance, and allows for 'Big Data' to be used to guide the investment decision.

Exantas logo

Flower Street Labs

Flower Street Labs is a company dedicated to overcoming the obstacles that prevent individuals from making a real difference to their environmental impact through small changes to their everyday habits. First off, we're rethinking the delivered meal kit to re-engage customers with their food and the impact of eating sustainably. We provide educational meal kits that introduce customers to healthy, delicious and sustainable plant-based cooking at their convenience, all sourced from seasonal, local Cambridge produce. The kits are personalised to each customer and respond to their changing needs (based on prior consumption) each week, to help everyone eat a sustainable, balanced diet. 

Flower Street Labs logo


Kvasir is a company focusing on building scalable semantic analytical platform. The company aims to provide the most efficient platform for content providers to organise their gigantic content repository. Kvasir also allows its users to quickly identify and explore the topics they are interested in on the internet. The core technology for Kvasir is built atop of state-of-the-art machine learning, system and networking science, making it possible to extend the search services to the network edges.


The vision of MicroInventa is to predict, isolate and grow valuable bacterial strains from the human intestinal microbiome for the purpose of therapeutic microbiome engineering.

The last decade of research has brought a tremendous surge in our understanding of the intestinal microbiome and its role in a wide range of human diseases. Metagenomic studies have linked disturbances in the bacterial composition of the intestinal microbiome to various health conditions, including allergies, gastrointestinal disorders, obesity, and cancer.

These findings have incited hopes for a rapid clinical development of microbiome-based therapies. Currently, the only approved microbiome therapy approved by the FDA is faecal microbiota transplantation (FMT). FMT is becoming a viable, and effective treatment for recurrent Clostridium difficile infection.  However, widespread therapeutic application of FMT is hampered by difficulties to standardise and control the procedure, since it involves the transfer of a large number of bacteria, viruses, and other eukaryotes, not all of which are needed or tolerated by the recipient.

A promising alternative strategy for treating these conditions is to supplement and eliminate specific beneficial and pathogenic bacterial strains, respectively, with the goal of re-establishing a healthy microbiome composition. Importantly, gut bacteria secrete metabolites with therapeutic value. MicroInventa uses algorithms to predict the presence of biosynthetic gene clusters for valuable metabolites and is building cutting-edge microfluidic technology to isolate bacterial strains from the gut that release these metabolites. Using this approach, we aim to develop the next-generation probiotic and postbiotic drugs for the treatment of microbiome-associated diseases.

Micro Inventa logo

Obsequio Software

Obsequio Software is a consent management platform, helping organisations through the full consent lifecycle with customers. 

Using Obsequio you can transparently and comprehensively detail your data processing intentions with new customers/prospects, give them control over which data you can process, for what purpose, over what period and make decisions on any 3rd party sharing.

Once your relationship with your customer is active, the ongoing management of consent, and the rights customers have, is a fundamental principle of the GDPR. Your customers can change their preferences whenever they need, submit data subject access requests, withdraw consent and make data portability requests.

Effective compliance efforts are dependent on robust processes. Providing a single portal for both you and your customers to manage the consent lifecycle together will streamline processes and reduce risk of error/missed information.

Through Obsequio it is easy for compliance teams to monitor request dates and time since. Needing to make the withdrawal of consent as easy as giving consent is further supported in Obsequio, following the same process with the same number of clicks for either.

Obsequio is specifically designed to manage the full consent lifecycle between you and your customer. A dedicated platform to help you do consent well.

Obsequio Software logo

Pentail Enzymes

We are a biotechnology company harnessing the power of enzymes to improve human health. Pentail's primary goal is to engineer and produce enzymes that target harmful substances in the human body for rapid elimination. Our prototype enzymes are being developed to neutralise a range of misused drugs, including prescription and over-the-counter medicines, which when overdosed can often lead to death or permanent organ damage. As the incidence of drug intoxication reaches epidemic levels worldwide, with significant health and social costs, our technology will provide an accessible tool for emergency services, ultimately helping to save lives.

Pentail Enzymes logo

POCKIT diagnostics

POCKIT diagnostics is a UK- and Ireland-based startup company aimed at improving diagnosis of brain stroke. Stroke is the third leading cause of death in the Western world and the first cause of physical disability and dementia in adults. Every year 15 million people in the world suffer a stroke; of these, five million die and another five million suffer permanent disability as a consequence of the stroke. Events of brain stroke can occur upon blockage or rupture of blood vessels, giving rise to ischemic stroke (AIS) or intracerebral haemorrhage (ICH), respectively. Patients suffering from AIS or ICH are treated with thrombolytic or pro-coagulant therapy, respectively. Early and reliable diagnosis of the type of stroke is fundamental, as a very narrow time window (four and a half hours) is available for the treatment to be delivered before brain damage becomes permanent. Accurate diagnosis of stroke is paramount, as erroneous administration of thrombolytic or pro-coagulant agents can lead to permanent disability or death. Currently, diagnosis of stroke is performed with computed tomography (CT), which has a high sensitivity for the diagnosis of ICH, but not of AIS. Moreover, CT takes valuable time and is not always readily available in emergency situations, thus delaying treatment of stroke patients and increasing the risk of stroke morbidity and mortality. 

So how is POCKIT going to improve this? After an ischemic or haemorrhagic stroke, specific molecules (biomarkers) are released into our blood. POCKIT is developing a diagnostic device for the rapid diagnosis of AIS and ICH patients. Our innovation is the application of rapid immune-based detection of stroke-specific biomarkers to provide diagnosis of stroke in less than 20 minutes. This diagnostic application can be operated by anyone without the use of laboratory equipment, or individuals trained in chemical analysis. Moreover, our device will be very cheap and highly portable, being able to fit in your pocket. In contrast with other diagnostic tools for stroke that deploy individual or small sets of biomarkers for stroke diagnosis, our device can detect up to 10 different biomarkers, thus significantly improving specificity and sensitivity of diagnosis. We have developed a panel of positive and negative biomarkers for AIS and ICH, potentially allowing to distinguish these conditions univocally. The combination of a rapid diagnostic device, together with our unique panel of stroke subtype-specific biomarkers will allow accurate, fast and cheap diagnosis of stroke patients, potentially leading to faster treatment and reducing disability and death of stroke patients.

Pockit diagnostics logo


Qureight is a clinical data curation and analytics company which works in partnership with healthcare bodies and software developers in the field of artificial intelligence. 

Through advanced infrastructure, coupled with technical and clinical expertise, the company performs annotation and analysis of anonymised data. Qureight exploits the value of data in their entirety and allows testing of machine learning algorithms, by collaborating with drug or technology companies, healthcare and academic institutions.

Qureight's mission is to combine technology and life sciences to generate new knowledge and transform the way we use clinical data.

Qureight logo creates optimisation technology for the next generation of data infrastructure and is the maker of the first industrial strength deep reinforcement learning library. Today, applications run in software containers on a growing range of devices and hosts ranging from local and remote servers to different cloud service providers and edge devices. is building software which learns optimal device assignments for software tasks and adjusts human resource requests to minimise energy consumption, hosting cost and resource usage. logo

Syrona Women

Syrona Women, a non-invasive, rapid diagnostic tool to help women better manage their own reproductive health both in the comfort of their own homes and future use by physicians in clinical settings. Syrona leverages the latest diagnostic technology combined with a unique sample which enables detection of multiple novel biomarkers indicative of STIs and reproductive cancers.

Visit the Syrona Women website

Syrona Women logo


UserContext.AI are a UK-based, deep technology company that builds next generation intelligent services to enable businesses to better understand the needs and interests of their users. They devise machine learning based online services that can automatically detect the task the user is trying to achieve when they interact with an online system (e.g. a search engine, a chatbot, an intelligent assistant, a web portal, etc.) and provide them with better contextual assistance that can help towards completing their tasks with very little effort.

User Context AI logo